Axogen, Inc. Common Stock (AXGN) — 分析摘要
Axogen, Inc. Common Stock(AXGN)的市值为2.10十亿美元,最近一年的营收同比增长了+20.2%。净利润率为-7.0%。当前市盈率为-66.8倍。
核心要点
- 营收同比变化+20.2%
- 净利润率-7.0%
- 市盈率-66.8倍
与ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS板块的其他公司相比,AXGN的营收增长为+20.2%,市盈率为-66.8倍。
Axogen, Inc. Common Stock (AXGN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -1.5x — 盈利不足以覆盖利息支出
净利润较上一期下降 100.3%。
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
行业
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
员工人数
622
总部
ALACHUA, FL
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
N/A
股息收益率
N/A
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。